Pediatric Acute Leukemia (PedAL) Screening Trial - Developing New Therapies for Relapsed Leukemias

This study is called a screening study and the purpose of this study to find better ways to diagnose and treat leukemia that has come back after treatment or difficult to treat. Bone marrow, blood, and medical information about cancer and treatment will be collected. The results from this screening study may give other information about leukemia that is important when deciding how to best treat leukemia.

Are you Eligible? (Inclusion Criteria)

• Patients must be 21 years of age or younger
• Patient must have one of the following: A. Patient has known or suspected relapsed/refractory (including primary refractory) AML. B. Patient has known or suspected relapsed/refractory (including primary refractory) myeloid leukemia of Down syndrome. C. Patient has known or suspected relapsed ALL that meets one of the following criteria: 1. Second or greater B-ALL medullary relapse, excluding KMT2Ar. 2. Any first or greater B-ALL medullary relapse involving KMT2Ar. 3. Any first or greater T-ALL medullary relapse with or without KMT2Ar. D. Patient has known or suspected relapsed/refractory (including primary refractory) mixed phenotype acute leukemia. E. Patient has known or suspected de novo or relapsed/refractory (including primary refractory) treatment related AML.